Evaluation of genetic association of neurodevelopment and neuroimmunological genes with antipsychotic treatment response in schizophrenia in indian populations

Molecular Genetics and Genomic Medicine

Volumn 4, Issue 1, 2016, Pages 18-27

  Jajodia, Ajay ^a   Kaur, Harpreet ^a   Kumari, Kalpana ^b   Kanojia, Neha ^a   Gupta, Meenal ^a   Baghel, Ruchi ^a   Sood, Mamta ^b   Jain, Sanjeev ^c   Chadda, Rakesh K ^b   Kukreti, Ritushree ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Antipsychotic; Meta analysis; Neurodevelopment; Pharmacogenomics; Severity

Indexed keywords

EID: 84974799451     PISSN: None     EISSN: 23249269     Source Type: Journal    
DOI: 10.1002/mgg3.169     Document Type: Article

References (63)

1. Adkins D. E., Khachane A. N., McClay J. L., Aberg K., Bukszar J., Sullivan P. F., et al. 2012. SNP‐based analysis of neuroactive ligand‐receptor interaction pathways implicates PGE2 as a novel mediator of antipsychotic treatment response: Data from the CATIE study. Schizophr. Res. 135:200–201.
2. Altamura A. C., Pozzoli S., Fiorentini A., and Dell'osso B. 2013. Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology. Prog. Neuropsychopharmacol. Biol. Psychiatry 42:63–70.
3. Arranz M. J., and de Leon J. 2007. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry 12:707–747.
4. Ayalew M., Le-Niculescu H., Levey D. F., Jain N., Changala B., Patel S. D., et al. 2012. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol. Psychiatry 17:887–905.
5. Banerjee A., Macdonald M. L., Borgmann-Winter K. E., and Hahn C. G. 2010. Neuregulin 1‐erbB4 pathway in schizophrenia: from genes to an interactome. Brain Res. Bull. 83:132–139.
6. Barrett J. C., Fry B., Maller J., and Daly M. J. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265.
7. Barros C. S., Calabrese B., Chamero P., Roberts A. J., Korzus E., Lloyd K., et al. 2009. Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. Proc. Natl Acad. Sci. USA 106:4507–4512.
8. Beumer W., Drexhage R. C., De Wit H., Versnel M. A., Drexhage H. A., and Cohen D. 2012. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 37:1901–1911.
9. Bishop J. R., Ellingrod V. L., Moline J., and Miller D. 2005. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr. Res. 77:253–260.
10. Bjarnadottir M., Misner D. L., Haverfield-Gross S., Bruun S., Helgason V. G., Stefansson H., et al. 2007. Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1 +/‐ knock‐outs compared with wild‐type mice. J. Neurosci. 27:4519–4529.
11. Boyle A. P., Hong E. L., Hariharan M., Cheng Y., Schaub M. A., Kasowski M., et al. 2012. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 22:1790–1797.
12. Busner J., and Targum S. D. 2007. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 4:28–37.
13. Chen S., Velardez M. O., Warot X., Yu Z. X., Miller S. J., Cros D., et al. 2006. Neuregulin 1‐erbB signaling is necessary for normal myelination and sensory function. J. Neurosci. 26:3079–3086.
14. Chen L., Ascher-Svanum H., Stauffer V., Kinon B. J., Kollack-Walker S., and Ruberg S. 2009. Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods. Schizophr. Res. 113:34–40.
15. Deng C., Pan B., Engel M., and Huang X. F. 2013. Neuregulin‐1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway. Psychopharmacology 226:201–215.
16. Emsley R., Rabinowitz J., and Medori R. 2006. Time course for antipsychotic treatment response in first‐episode schizophrenia. Am. J. Psychiatry 163:743–745.
17. Estep K. G., Fliri A. F. J., and O'donnell C. J. 2008. Sulfonamides and pharmaceutical compositions there of WO 2008120093 A1.
18. Fribourg M., Moreno J. L., Holloway T., Provasi D., Baki L., Mahajan R., et al. 2011. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 147:1011–1023.
19. Gupta M., Jain S., Moily N. S., Kaur H., Jajodia A., Purushottam M., et al. 2012. Genetic studies indicate a potential target 5‐HTR(3B) for drug therapy in schizophrenia patients. Am. J. Med. Genet. B Neuropsychiatr. Genet. 159B:1006–1008.
20. Hope S., Melle I., Aukrust P., Steen N. E., Birkenaes A. B., Lorentzen S., et al. 2009. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord. 11:726–734.
21. Iasevoli F., Tomasetti C., Buonaguro E. F., and de Bartolomeis A. 2014. The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Curr. Neuropharmacol. 12:219–238.
22. Ikeda M., Tomita Y., Mouri A., Koga M., Okochi T., Yoshimura R., et al. 2010. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case‐control association approaches. Biol. Psychiatry 67:263–269.
23. Indian Genome Variation Consortium 2008. Genetic landscape of the people of India: a canvas for disease gene exploration. J. Genet. 87:3–20.
24. Jajodia A., Kaur H., Kumari K., Gupta M., Baghel R., Srivastava A., et al. 2015. Evidence for schizophrenia susceptibility alleles in the Indian population: an association of neurodevelopmental genes in case‐control and familial samples. Schizophr. Res. 162:112–117.
25. Jha P., Sinha S., Kanchan K., Qidwai T., Narang A., Singh P. K., et al. 2012. Deletion of the APOBEC3B gene strongly impacts susceptibility to falciparum malaria. Infect. Genet. Evol. 12:142–148.
26. Kaur H., Jajodia A., Grover S., Baghel R., Jain S., and Kukreti R. 2014. Synergistic association of PI4KA and GRM3 genetic polymorphisms with poor antipsychotic response in south Indian schizophrenia patients with low severity of illness. Am. J. Med. Genet. B Neuropsychiatr. Genet. 165B:635–646.
27. Kinon B. J., Chen L., Stauffer V. L., Sniadecki J., Ascher-Svanum H., Kollack-Walker S., et al. 2010. Early onset of antipsychotic action in schizophrenia: evaluating the possibility of shorter acute efficacy trials. J. Clin. Psychopharmacol. 30:286–289.
28. Lavedan C., Licamele L., Volpi S., Hamilton J., Heaton C., Mack K., et al. 2009. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol. Psychiatry 14:804–819.
29. Lehman A. F., Lieberman J. A., Dixon L. B., McGlashan T. H., Miller A. L., Perkins D. O., et al., American Psychiatric Association, and Steering Committee on Practice Guidelines. 2004. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 161(Suppl 2):1–56.
30. Lieberman J. A., Stroup T. S., McEvoy J. P., Swartz M. S., Rosenheck R. A., Perkins D. O., et al., and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353:1209–1223.
31. Liu Y., Li Z., Zhang M., Deng Y., Yi Z., and Shi T. 2013. Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis. BMC Med. Genomics 6(Suppl 1):S17.
32. McClay J. L., Adkins D. E., Aberg K., Stroup S., Perkins D. O., Vladimirov V. I., et al. 2011. Genome‐wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol. Psychiatry 16:76–85.
33. Mei L., and Xiong W. C. 2008. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci. 9:437–452.
34. Meltzer H. Y. 2008. Schizophrenia in Ebert M. H., editor;, Loosen P. T., editor;, Nurcombe B., editor; and Leckman J. F., editor., eds. Current diagnosis and treatment: psychiatry. McGraw‐Hill, New York.
35. Moghaddam B. 2003. Bringing order to the glutamate chaos in schizophrenia. Neuron 40:881–884.
36. Muhleisen T. W., Leber M., Schulze T. G., Strohmaier J., Degenhardt F., Treutlein J., et al. 2014. Genome‐wide association study reveals two new risk loci for bipolar disorder. Nat. Commun. 5:3339.
37. Mundo E., Altamura A. C., Vismara S., Zanardini R., Bignotti S., Randazzo R., et al. 2005. MCP‐1 gene (SCYA2) and schizophrenia: a case‐control association study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 132B:1–4.
38. Need A. C., Keefe R. S., Ge D., Grossman I., Dickson S., McEvoy J. P., et al. 2009. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur. J. Hum. Genet. 17:946–957.
39. Newton S. S., and Duman R. S. 2007. Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS Drugs 21:715–725.
40. Ng M. Y., Levinson D. F., Faraone S. V., Suarez B. K., DeLisi L. E., Arinami T., et al. 2009. Meta‐analysis of 32 genome‐wide linkage studies of schizophrenia. Mol. Psychiatry 14:774–785.
41. Paul-Samojedny M., Kowalczyk M., Suchanek R., Owczarek A., Fil-Danilow A., Szczygiel A., et al. 2010. Functional polymorphism in the interleukin‐6 and interleukin‐10 genes in patients with paranoid schizophrenia–a case‐control study. J. Mol. Neurosci. 42:112–119.
42. Petryshen T. L., Middleton F. A., Kirby A., Aldinger K. A., Purcell S., Tahl A. R., et al. 2005. Support for involvement of neuregulin 1 in schizophrenia pathophysiology. Mol. Psychiatry 10:366–374, 328.
43. Potvin S., Stip E., Sepehry A. A., Gendron A., Bah R., and Kouassi E. 2008. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 63:801–808.
44. Price A. L., Patterson N. J., Plenge R. M., Weinblatt M. E., Shadick N. A., and Reich D. 2006. Principal components analysis corrects for stratification in genome‐wide association studies. Nat. Genet. 38:904–909.
45. Pritchard J. K., Stephens M., and Donnelly P. 2000. Inference of population structure using multilocus genotype data. Genetics 155:945–959.
46. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M. A., Bender D., et al. 2007. PLINK: a tool set for whole‐genome association and population‐based linkage analyses. Am. J. Hum. Genet. 81:559–575.
47. Putnam D. K., Sun J., and Zhao Z. 2011. Exploring schizophrenia drug‐gene interactions through molecular network and pathway modeling. AMIA Annu. Symp. Proc. 2011:1127–1133.
48. Reich D., Thangaraj K., Patterson N., Price A. L., and Singh L. 2009. Reconstructing Indian population history. Nature 461:489–494.
49. Sacchetti E., Bocchio-Chiavetto L., Valsecchi P., Scassellati C., Pasqualetti P., Bonvicini C., et al. 2007. G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: meta‐analysis plus association study. Brain Behav. Immun. 21:450–457.
50. Schizophrenia Psychiatric Genome‐Wide Association Study C. 2011. Genome‐wide association study identifies five new schizophrenia loci. Nat. Genet. 43:969–976.
51. Schwarz M. J., Kronig H., Riedel M., Dehning S., Douhet A., Spellmann I., et al. 2006. IL‐2 and IL‐4 polymorphisms as candidate genes in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 256:72–76.
52. Shamir A., Kwon O. B., Karavanova I., Vullhorst D., Leiva-Salcedo E., Janssen M. J., et al. 2012. The importance of the NRG‐1/ErbB4 pathway for synaptic plasticity and behaviors associated with psychiatric disorders. J. Neurosci. 32:2988–2997.
53. Shi Y., Li Z., Xu Q., Wang T., Li T., Shen J., et al. 2011. Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nat. Genet. 43:1224–1227.
54. Shiota S., Tochigi M., Shimada H., Ohashi J., Kasai K., Kato N., et al. 2008. Association and interaction analyses of NRG1 and ERBB4 genes with schizophrenia in a Japanese population. J. Hum. Genet. 53:929–935.
55. Stefansson H., Sarginson J., Kong A., Yates P., Steinthorsdottir V., Gudfinnsson E., et al. 2003. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am. J. Hum. Genet. 72:83–87.
56. Tybura P., Samochowiec A., Beszlej A., Grzywacz A., Mak M., Frydecka D., et al. 2012. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacol. Rep. 64:528–535.
57. Ward L. D., and Kellis M. 2012. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 40(Database issue):D930–D934.
58. Woods S. W. 2003. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 64:663–667.
59. Xiong Y., Wei Z., Huo R., Wu X., Shen L., Li Y., et al. 2014. A pharmacogenetic study of risperidone on chemokine (C‐C motif) ligand 2 (CCL2) in Chinese Han schizophrenia patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 51:153–158.
60. Xu W., Cohen-Woods S., Chen Q., Noor A., Knight J., Hosang G., et al. 2014. Genome‐wide association study of bipolar disorder in Canadian and UK populations corroborates disease loci including SYNE1 and CSMD1. BMC Med. Genet. 15:2.
61. Zandi P. P., and Judy J. T. 2010. The promise and reality of pharmacogenetics in psychiatry. Clin. Lab. Med. 30:931–974.
62. Zheng Y., Balabhadrapatruni S., Masumura C., Darlington C. L., and Smith P. F. 2011. Effects of the putative cognitive‐enhancing ampakine, CX717, on attention and object recognition memory. Curr. Alzheimer Res. 8:876–882.
63. Zoghbi H. Y., and Bear M. F. 2012. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb. Perspect. Biol. 4 pii: a009886.